Company Description

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.

The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.

Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Nasus Pharma Ltd.

Country	Israel
Founded	2019
IPO Date	Aug 14, 2025
Industry	Drug Manufacturers - General
Sector	Healthcare
Employees	2
CEO	Dan Teleman

Contact Details

Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel
Phone	972 3 573 6632
Website	nasuspharma.com

Stock Details

Ticker Symbol	NSRX
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$8.00
CIK Code	0002029039
CUSIP Number	001218155
ISIN Number	IL0012181553
Employer ID	51-6022712
SIC Code	2834

Key Executives

Name	Position
Dan Teleman MBA M.Sc.	Chief Executive Officer and Director
Ehud Moshe Gilboa MBA	Co-Founder and Executive Chairman
Dr. Dalia Megiddo M.B.A., M.D., Ph.D.	Co-Founder, Director, Chief Medical Officer and Chief Development Officer?
Oren Elmaliach	Director of Finance
Dr. Galia Temtsin Kryaz Ph.D.	Director of CMC and Product Development

Latest SEC Filings

Date	Type	Title
Nov 18, 2025	6-K	Report of foreign issuer
Nov 13, 2025	SCHEDULE 13G	Filing
Nov 12, 2025	SCHEDULE 13G	Filing
Nov 10, 2025	SCHEDULE 13G	Filing
Nov 3, 2025	6-K	Report of foreign issuer
Oct 8, 2025	6-K	Report of foreign issuer
Sep 30, 2025	6-K	Report of foreign issuer
Sep 5, 2025	6-K	Report of foreign issuer
Aug 20, 2025	SCHEDULE 13G	Filing
Aug 14, 2025	6-K	Report of foreign issuer

View All SEC Filings